Stay updated on Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page
- CheckyesterdayChange DetectedThis change updates the site/revision version shown in the page footer from v3.5.2 to v3.5.3, indicating a minor release of the ClinicalTrials.gov page display.SummaryDifference0.1%

- Check8 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check37 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. This update appears to be an internal version change to the page.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check73 days agoChange DetectedA new site Revision: v3.4.2 appears, and the previous government funding notice (and Revision: v3.4.1) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedA site-wide notice about government funding lapse and NIH Clinical Center status was added, and the system revision updated to v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.